

# Converting patent data into 3D maps of SAR

Giovanna Tedesco<sup>†</sup>

<sup>†</sup> Cresset, New Cambridge House, Bassingbourn Road, Litlington, Cambridgeshire, SG8 0SS, UK

## Abstract

Activity Atlas<sup>1</sup> is a novel, qualitative method available in Forge<sup>2</sup>, Cresset's powerful workbench for ligand design and SAR analysis. Activity Atlas is particularly useful to condense large data tables into a single picture, summarizing structure-activity data into highly visual 3D maps that inform the design and optimization of new compounds. In this case study, Activity Atlas was used to analyze the Structure-Activity Relationships (SAR) of a large data set of Orexin 2 receptor ligands taken from the US patent literature, with the objective to quickly investigate and understand the electrostatic, hydrophobic and shape features underlying the receptor activity of a recently published scaffold.

## Introduction

Whenever a new research project is initiated, or transferred across teams, familiarization with the prior art for the project must be completed in the shortest possible time so as to avoid wasting resources investing in directions already explored in the past. Equally, new patent publications on a project of current interest can inform optimization decisions on an in house series.

Historical information, both in house and published, is often available in electronic format, however, exploring the known SAR for a target can be a tedious and time consuming exercise for the project team because of the volume of data implied.

Activity Atlas is a probabilistic method of analyzing the SAR of a set of aligned compounds as a function of their electrostatic, hydrophobic and shape properties. The method uses a Bayesian approach to take a global view of the data in a qualitative manner. Results are displayed using Forge's visualization capabilities

to gain a better understanding of the features which underlie the SAR of your compounds.

In this case study, the activity cliff summary method in Activity Atlas was used to find the critical SAR regions of a large data set of published Orexin 2 Receptor ligands. The objective was to understand the electrostatic, hydrophobic and shape features underlying receptor activity and to demonstrate the applicability of this method to the SAR analysis of large data sets.

## Crystal structure of Suvorexant bound to the human Orexin 2 receptor

The Orexin system is composed of two widely expressed G-protein coupled receptors: Orexin 1 and Orexin 2 receptors (OX<sub>1</sub>R and OX<sub>2</sub>R, respectively), which respond to two peptide agonists (orexin-A and orexin-B) in the central nervous system to regulate sleep and other behavioral functions in humans<sup>3</sup>. The structure of Suvorexant<sup>4</sup> (potent therapeutic inhibitor of the Orexin system) bound to human OX<sub>2</sub>R was recently solved<sup>5</sup> at 2.5Å resolution. The X-ray

structure (Figure 1) reveals how Suvorexant binds to OX<sub>2</sub>R adopting a pi-stacked horseshoe-like conformation deep in the orthosteric pocket, stabilizing a network of extracellular salt bridges and blocking transmembrane helix motions necessary for activation. Most of the ligand contacts involve van der Waals interactions or aromatic packing. Suvorexant's tertiary amide carbonyl forms a strong hydrogen bond with Asn324 (Figure 1) and only a few other direct polar interactions with the OX<sub>2</sub>R binding site. Several water-mediated hydrogen bonds form bridges between Suvorexant and polar amino acids such as Asn324 and His350.




Figure 1 – Crystal structure of Suvorexant bound to the human OX<sub>2</sub> receptor.

## Data set

A large data set of approximately 400 compounds with available OX<sub>2</sub>R data (expressed as nM K<sub>i</sub>) gathered from the 'US patent' data source was downloaded from BindingDB.<sup>6</sup> These records cover patent information published between 2013 and 2014 by Janssen<sup>7</sup> and Merck<sup>8</sup>.

The set is composed of two main chemical series: for both, the most potent compound

was selected as a reference structure for that series (Table 1).

## Conformation hunt and alignment of compounds

The two reference compounds in Table 1 were aligned to the published X-ray crystal structure of Suvorexant (PDB 4S0V) by field-based alignment within Forge following a 'very accurate but slow' conformation hunt:

- Max number of conformations: 1000
- RMS cut-off for duplicate conformers: 0.5
- Gradient cut-off for conformer minimization: 0.1 kcal/mol
- Energy window: 3 kcal/mol.



The 400 compounds in the data set were then aligned to the appropriate reference structure by maximum common substructure alignment following an 'accurate but slow' set-up for the conformation hunt:

- Max number of conformations: 200
- RMS cut-off for duplicate conformers: 0.5
- Gradient cut-off for conformer minimization: 0.1 kcal/mol
- Energy window: 3 kcal/mol.

'Permissive' maximum common substructure matching rules (in which substructure matches ignore element but take into account hybridization, so that for example cyclohexane matches morpholine but not benzene) were used for the alignment.

The use of a 3D similarity metric in Activity Atlas requires (as with 3D-QSAR) the generation of alignments for all compounds and can be sensitive to misalignment and alignment noise.

Table 1. The data sets and reference structures included in this case study.

Name	Reference structure	N. of compounds	Activity range (OX <sub>2</sub> R pKi)	US Patent Number
Janssen		377	5 - 8.5	8,653,263 B2
Merck		34	5 - 9	2013/0102619 A1

For this reason, visual inspection of alignments is recommended, to ensure that there are no anomalies present and that manual intervention can be used to improve sub-optimal alignments.

Accordingly, the alignment of some compounds were manually adjusted to increase consistency across the whole data set.

### Activity Atlas models

Activity Atlas models are calculated following a probabilistic approach which takes into account the probability that a molecule is correctly aligned, rather than assuming that the top scoring or the selected preferred alignment is the correct alignment.

This is done by associating a weight with each alignment based on its similarity score. Alignments with similarity higher than a certain threshold (which can either be automatically calculated by Forge, or manually defined by the user) are fully trusted. Alignments with similarity lower than the low similarity

threshold are not trusted and discarded. Linear scaling is applied to associate a proper weight to alignments which have an intermediate similarity score.

Likewise, a weight is also associated with each molecule based on its activity. Molecules whose activity is higher than a certain threshold (which again can either be automatically calculated by Forge, or manually defined by the user) are considered fully active. Molecules whose activity is lower than the low activity threshold are considered inactive. Molecules with intermediate activity are considered only partially active.

Activity Atlas calculates and displays as 3D visualizations the:

- ‘Activity cliff summary’: what do the activity cliffs tell us about the SAR?
- ‘Average of actives’: what do active molecules have in common?
- ‘Regions explored’: where have I been? For a new molecule, would making it increase our understanding?

The regions explored analysis also calculates a novelty score for each molecule.

In this case study, the activity cliff summary analysis was applied to both series with the objective of interpreting and understanding their SAR.




Figure 2. Reference compounds for each data set (grey) superimposed to the crystal structure of Suvorexant (pink) bound to the  $OX_2$  receptor (PDB code 4SOV).

## Results

Figure 2 shows the two reference compounds (grey) in Table 1 superimposed to the crystal structure of Suvorexant (pink) bound to the  $OX_2$  receptor. Both the Janssen and the Merck compounds superimpose very well with Suvorexant, with the tertiary amide carbonyl pointing towards Asn324 (which makes a hydrogen bond interaction with the corresponding carbonyl in Suvorexant). This may indicate a common binding mode for the two series of compounds.

This hypothesis will be further explored with the activity cliff summary analysis of Activity Atlas.

### Activity cliff summary analysis of the Janssen data set

The Janssen data set consists of 377 compounds spanning an  $OX_2$ R pKi range from 5 to 8.5.




Figure 3. Activity cliff summary 3D maps for the Janssen data set, superimposed to the most active compound ( $OX_2$ R pKi 8.5).

### SAR of left side phenyl ring

The activity cliff summary analysis for this data set indicates that  $OX_2$ R activity is increased by having a hydrophobic substituent on the *ortho* position of the left side phenyl ring, as shown by the favorable (green) areas in Figure 3.

The preferred decorations on this ring are characterized by a stronger positive (red) field at the edge of the *ortho* substituent, as well as by a stronger negative (cyan) field wrapping the *meta* and *ortho* substituents above and below the plane of the molecule.

As shown in Figure 4, large differences in the electrostatic fields surrounding the left side of the molecule are associated with dramatic changes in  $OX_2$ R pKi.

Accordingly, the choice of an appropriate heterocycle and electronegative groups such as small halogens for the decoration of the left side phenyl ring, which help creating the right

pattern of positive and negative electrostatic fields around the molecule, is crucial for modulating OX<sub>2</sub>R activity.




Figure 4. Electrostatic field differences for compound 362 compared to compound 614. Color coding: red, more positive fields; cyan, more negative fields.

### SAR of right side aromatic ring

Steric bulk and hydrophobicity on the *para* position of the pyrimidine ring on the right side of the molecule are also beneficial for OX<sub>2</sub>R, as shown by the green areas in Figure 3.

Also in this case the choice of an appropriate decoration can have a dramatic impact on pKi, as shown in Figure 5 below.




Figure 5. Steric bulk and hydrophobicity (gold field) in *para* position of the pyrimidine ring are beneficial for OX<sub>2</sub>R activity.

### Activity cliff summary analysis of the Merck data set




Figure 6. Activity cliff summary 3D maps for the Merck data set.

This data set is formed by 34 compounds spanning a 4-fold OX<sub>2</sub>R activity range (pKi from 5 to 9). The activity cliff summary analysis maps, shown in Figure 6, are quite different from those of the Janssen set.

This is surprising, given the excellent fit to Suvorexant of both the Janssen and the Merck reference structures (Figure 2), which seems to indicate a common binding mode for the two series.

### SAR of the left side phenyl ring

As for the SAR of the left side phenyl ring, the favorable positive and negative field areas associated with the *ortho* and *meta* substituents in the Janssen data set no longer appear, even though steric bulk/hydrophobicity in this position are still favorable (green areas).



There is instead a strong signal related to the *para* position. Bulky substituents in *para* are detrimental for OX<sub>2</sub>R activity (magenta areas), while those associated to a stronger positive (or weaker negative) field, shown in red, are beneficial for activity.

For example, as shown in Figure 7 below, compound 397 (*para*-Cl) is more active than 389, carrying a bulkier OEt which enters into the area of unfavorable (magenta) shape.




Figure 7. Steric bulk in the *para* position is detrimental for OX<sub>2</sub>R activity.  
Color coding: Magenta, unfavorable shape.

Compound 397 (*para*-Cl) is again more active than compound 387 (Figure 8), decorated with a CN which is only slightly bulkier than Cl, but associated to a more negative field.




Figure 8. A more negative field in the *para* position is detrimental for OX<sub>2</sub>R activity.  
Color coding: red, more positive fields; cyan, more negative fields.

However, a more in depth analysis of the Merck data set shows that only three different heterocyclic substituents have been explored in the *ortho* position of the left-side phenyl ring, namely pyridine, triazole and oxadiazole, with the latter tried only in one compound. As can be seen from the electrostatic field difference maps in Figure 9A, pyridine and triazole generate very similar electrostatic fields and are not surprisingly associated to similar OX<sub>2</sub>R pKi values. The same substituents were explored also in the Janssen set and also in that case were not associated to any significant change in activity. Pyrimidine and oxadiazole instead generate slightly more different electrostatic fields (Figure 9B) and this is reflected in a more




Figure 9A. Electrostatic field differences for compound 404 and compound 390.




Figure 9B. Electrostatic field differences for compound 407 and compound 408.  
Color coding: red, more positive fields; cyan, more negative fields.

marked difference in OX<sub>2</sub>R pKi in the Merck series.

It is possible that a positive field area is beneficial for activity for both series, but that in the Merck set SAR this effect cannot be appreciated for lack of sufficient chemical exploration.

### **SAR of the right side pyridine**

Going back to the activity cliff summary maps in Figure 6, the lack of SAR on the right side pyridine is to be expected, as this substituent does not vary across the data set (Figure 6).

### **SAR of the tertiary amide carbonyl**

The favorable negative field area associated with the tertiary amide carbonyl of the Merck compounds is consistent with the fact that in Suvorexant bound to OX<sub>2</sub>R this carbonyl makes an H-bond interaction with Asn324. Assuming a similar binding mode for the Merck compounds, decorations on the left side of the molecule which strengthen the negative field associated with the C=O are should be beneficial for activity.

## **Conclusions**

Activity Atlas is a new method for summarizing the SAR for a series into a visual 3D model that can be used to inform new molecule design. In this case study, Activity Atlas proved to be an invaluable tool for quickly summarizing, analyzing and understanding the SAR of a large collection of compounds gathered from US patent information.

In particular, the Activity Atlas activity cliff summaries highlighted in quick and highly visual manner both the commonalities across the series and the dissimilarities in SAR potentially related to minor changes in the binding mode.

Both represent important information for deciding future directions for the project: the commonalities potentially highlighting areas of chemical exploration so far unexploited; while the dissimilarities may offer a way of further refining the overall profile of the chemical series of interest.

## **References and Links**

1. <http://www.cresset-group.com/activity-atlas/>
2. <http://www.cresset-group.com/products/forge/>
3. Li, J., *et al.*, *Br. J. Pharmacol.* **171**, 332-350 (2014)
4. Winrow, C.J., *et al.*, *Br. J. Pharmacol.* **171**, 283-293 (2014)
5. Yin, J., *et al.*, *Nature* **519**, 247-250 (2015)
6. <https://www.bindingdb.org>
7. US Patent 8,653,263 B2
8. US Patent 2013/0102619 A1